Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial.
Summary
In a multicenter phase 3 RCT, administering anti–PD-1–based immunochemotherapy before 15:00 significantly improved PFS (11.3 vs 5.7 months; HR 0.40) and OS (28.0 vs 16.8 months; HR 0.42) in advanced NSCLC without new safety concerns. Immune-related adverse events were similar across groups.
Key Findings
- Early ToD immunochemotherapy improved median PFS to 11.3 vs 5.7 months (HR 0.40; P<0.001).
- Early ToD improved median OS to 28.0 vs 16.8 months (HR 0.42; P<0.001).
- No new safety signals; immune-related adverse events were similar between groups.
Clinical Implications
For advanced NSCLC receiving anti–PD-1–based chemoimmunotherapy, scheduling infusions earlier in the day may be adopted to maximize efficacy without added toxicity. Oncology services should consider operational shifts to accommodate morning administrations.
Why It Matters
This is a large, randomized, phase 3 chronotherapy trial showing clinically meaningful survival gains with a simple scheduling change. It could immediately influence infusion timing policies.
Limitations
- Open-label design could introduce performance bias.
- Driver mutation–negative population; generalizability to broader NSCLC subsets needs confirmation.
Future Directions
Validate ToD effects across different immunotherapy backbones, PD-L1 strata, and real-world settings; assess mechanisms (circadian immune dynamics) and cost–operational impacts of morning scheduling.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- I - Phase 3 randomized controlled trial providing highest-level evidence for intervention efficacy.
- Study Design
- OTHER